A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines
- Authors
- Baik, Yeong Ok; Choi, Seuk Keun; Olveda, Remigio M.; Espos, Roberto A.; Ligsay, Antonio D.; Montellano, May B.; Yeam, Jong Sun; Yang, Jae Seung; Park, Ju Yeon; Kim, Deok Ryun; Desai, Sachin N.; Singh, Ajit Pal; Kim, Ick Young; Kim, Chan Wha; Park, Sue-nie
- Issue Date
- 17-11월-2015
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Oral cholera vaccine; Safety; Immunogenicity; Euvichol; Shanchol; Children; Adults
- Citation
- VACCINE, v.33, no.46, pp.6360 - 6365
- Indexed
- SCIE
SCOPUS
- Journal Title
- VACCINE
- Volume
- 33
- Number
- 46
- Start Page
- 6360
- End Page
- 6365
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/91887
- DOI
- 10.1016/j.vaccine.2015.08.075
- ISSN
- 0264-410X
- Abstract
- Background: Currently, there are two oral cholera vaccines (OCV) that are prequalified by the World Health Organization. Both (Dukoral and Shanchol) have been proven to be safe, immunogenic, and effective. As the global supply of OCV remains limited, we assessed the safety and immunogenicity of a new low cost, killed, bivalent OCV (Euvichol) in the Philippines. Methods: The randomized controlled trial was carried out in healthy Filipino adults and children. Two doses of either the current WHO prequalified OCV (Shanchol) or the same composition OCV being considered for WHO prequalification (Euvichol) were administered to participants. Results: The pivotal study was conducted in total of 1263 healthy participants (777 adults and 486 children). No serious adverse reactions were elicited in either vaccine groups. Vibriocidal antibody responses to V. cholerae O1 Inaba following administration of two doses of Euvichol were non-inferior to those of Shanchol in adults (82% vs 76%) and children (87% vs 89%). Similar findings were observed for O1 Ogawa in adults (80% vs 74%) and children (91% vs 88%). Conclusion: A two dose schedule with Euvichol induces a strong vibriocidal response comparable to those elicited by the currently WHO prequalified OCV, Shanchol. Euvichol will be an oral cholera vaccine suitable for use in lower income countries, where cholera still has a significant economic and public health impact. (C) 2015 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Life Sciences > 1. Journal Articles
- College of Life Sciences and Biotechnology > Division of Life Sciences > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/91887)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.